Recursion Pharmaceuticals reported mixed Q2 results, with revenue declining to $7.67 million and a narrowed net loss of $131.01 million. The company achieved key milestones in its AI-driven drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results